The DOI matches its Crossref record; 31 of the 34 references it cites were found in a registry or an index.
Disease-Specific Induced Pluripotent Stem Cells.
Open accessAbstract
Tissue culture of immortal cell strains from diseased patients is an invaluable resource for medical research but is largely limited to tumor cell lines or transformed derivatives of native tissues. Here we describe the generation of induced pluripotent stem (iPS) cells from patients with a variety of genetic diseases with either Mendelian or complex inheritance; these diseases include adenosine deaminase deficiency-related severe combined immunodeficiency (ADA-SCID), Shwachman-Bodian-Diamond syndrome (SBDS), Gaucher disease (GD) type III, Duchenne (DMD) and Becker muscular dystrophy (BMD), Parkinson disease (PD), Huntington disease (HD), juvenile-onset, type 1 diabetes mellitus (JDM), Down syndrome (DS)/trisomy 21, and the carrier state of Lesch-Nyhan syndrome. Such disease-specific stem cells offer an unprecedented opportunity to recapitulate both normal and pathologic human tissue formation in vitro, thereby enabling disease investigation and drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The first iPSCs reprogrammed from an individual with DS were reported in 2008 (Park et al., 2008) and multiple lines have been created from multiple different individuals since then.”
From Neurodevelopment in Down syndrome: Concordance in humans and models (2022) · cites this paper as Park et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of pluripotent stem cells from adult human fibroblasts by defined factors.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/s0093-3619(08)70915-8 · Cited by 19,664 · cited 2×
“In contrast, introducing a set of transcription factors linked to pluripotency can directly reprogram human somatic cells to produce induced pluripotent stem (iPS) cells, a method that has been achieved by several groups worldwide (Lowry et al., 2008; Park et al., 2008b; Takahashi et al., 2007; Yu et al., 2007).”
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310 · cited 2×
“In contrast, introducing a set of transcription factors linked to pluripotency can directly reprogram human somatic cells to produce induced pluripotent stem (iPS) cells, a method that has been achieved by several groups worldwide (Lowry et al., 2008; Park et al., 2008b; Takahashi et al., 2007; Yu et al., 2007).”
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436 · cited 12×
“Following 2 to 3 weeks of culture in hES cell-supporting conditions, compact refractile ES-like colonies emerged among a background of fibroblasts, as previously described (Park et al., 2008a, 2008b).”
InfluentialSelf-citationSite-directed mutagenesis by gene targeting in mouse embryo-derived stem cells
Thomas, K. R., & Capecchi, M. R. (1987) · Cell · doi:10.1016/0092-8674(87)90646-5 · Cited by 2,355 · cited 1×
“Strategies for inducing specific mutation or gene repair by homologous recombination were first established for the HPRT locus (Doetschman et al., 1987, 1988; Thomas and Capecchi, 1987).”
Murry, C. E., & Keller, G. M. (2008) · Cell · doi:10.1016/j.cell.2008.02.008 · Cited by 1,760 · cited 1×
“Human embryonic stem cells isolated from excess embryos from in vitro fertilization clinics represent an immortal propagation of pluripotent cells that theoretically can generate any cell type within the human body (Lerou et al., 2008; Murry and Keller, 2008).”
Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification
Chamberlain, J. S., Gibbs, R. A., Rainer, J. E., Nguyen, P. N., & Caskey, C. T. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.23.11141 · Cited by 1,271 · cited 2×
“Multiplex PCR analysis with primer sets amplifying several (but not all) intragenic intervals of the dystrophin gene (Beggs et al., 1990; Chamberlain et al., 1988) revealed the deletion of exons 45–52 in the iPS cells derived from a patient with Duchenne muscular dystrophy (DMD; Figure 1C).”
Generation of human induced pluripotent stem cells from dermal fibroblasts
Lowry, W. E., Richter, L., Yachechko, R., Pyle, A. D., Tchieu, J., Sridharan, R., Clark, A. T., & Plath, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711983105 · Cited by 1,041 · cited 2×
“In contrast, introducing a set of transcription factors linked to pluripotency can directly reprogram human somatic cells to produce induced pluripotent stem (iPS) cells, a method that has been achieved by several groups worldwide (Lowry et al., 2008; Park et al., 2008b; Takahashi et al., 2007; Yu et al., 2007).”
Sequential Expression of Pluripotency Markers during Direct Reprogramming of Mouse Somatic Cells
Brambrink, T., Foreman, R. K., Welstead, G. G., Lengner, C. J., Wernig, M., Suh, H., & Jaenisch, R. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.01.004 · Cited by 839 · cited 2×
“…from a carrier of Lesch-Nyhan syndrome using five doxycycline-inducible lentiviral vectors (OCT4, SOX2, KLF4, c-MYC, and NANOG), a strategy that has been used to isolate murine iPS cells (Brambrink et al., 2008; Stadtfeld et al., 2008) but previously had not been attempted with human somatic cells.”
Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse
Stadtfeld, M., Maherali, N., Breault, D. T., & Hochedlinger, K. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.02.001 · Cited by 823 · cited 4×
“…from a carrier of Lesch-Nyhan syndrome using five doxycycline-inducible lentiviral vectors (OCT4, SOX2, KLF4, c-MYC, and NANOG), a strategy that has been used to isolate murine iPS cells (Brambrink et al., 2008; Stadtfeld et al., 2008) but previously had not been attempted with human somatic cells.”
MethodInfluentialSelf-citationNon–cell autonomous effect of glia on motor neurons in an embryonic stem cell–based ALS model
Di Giorgio, F. P., Carrasco, M. A., Siao, M. C., Maniatis, T., & Eggan, K. (2007) · Nature Neuroscience · doi:10.1038/nn1885 · Cited by 799
Research works printed but not linked: 1
- Hirschhorn, 1993, Two new mutations at the adenosine deaminase (ADA) locus (Q254X and del nt1050–54) unusual for not being missense mutations, Hum. Mutat., 2, 320, 10.1002/humu.1380020415 · DOI
Cited by
Sorted by citations
Items 201–300 of 1,010
Stem cell models of Alzheimer’s disease: progress and challenges
Arber, C., Lovejoy, C., & Wray, S. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0268-4 · Cited by 143
Hossini, A. M., Megges, M., Prigione, A., Lichtner, B., Toliat, M. R., Wruck, W., Schröter, F., Nüernberg, P., Kroll, H., Makrantonaki, E., et al. (2015) · BMC Genomics · doi:10.1186/s12864-015-1262-5 · Cited by 139
Opportunities for Use of Human iPS Cells in Predictive Toxicology
Anson, B. D., Kolaja, K. L., & Kamp, T. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.9 · Cited by 145
Complex Tissue and Disease Modeling using hiPSCs
Passier, R., Orlova, V., & Mummery, C. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.02.011 · Cited by 142
Kim, Y. J., Lim, H., Li, Z., Oh, Y., Kovlyagina, I., Choi, I.-Y., Dong, X.-Z., & Lee, G. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.07.013 · Cited by 142
“Recent studies have shown that particular combinations of transcription factors can force human somatic cells into new identities, including pluripotent stem cells (Park et al., 2008; Takahashi and Yamanaka, 2006), postmitotic neurons (Pang et al., 2011), myoblasts (Schäfer et al., 1990), etc.”
BackgroundYanagimachi, M. D., Niwa, A., Tanaka, T., Honda‐Ozaki, F., Nishimoto, S., Murata, Y., Yasumi, T., Ito, J., Tomida, S., Oshima, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059243 · Cited by 163
“[15,31–34] Because patient- or disease-specific iPS cells will be an important resource for unraveling human immunological disorders, a robust and simple hematopoietic differentiation system that can reliably mimic in vivo hematopoiesis is necessary for this purpose.”
BackgroundStem Cells and Calcium Signaling
Tonelli, F. M. P., Santos, A. K., Gomes, D. A., Silva, S. L. D., Gomes, K. N., Ladeira, L. O., & Resende, R. R. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2888-2_40 · Cited by 138
“Today there is a large number of studies using these cells trying to understand mechanisms and to find a treatment for degenerative and genetic diseases is huge [22].”
BackgroundThe GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome
Contestabile, A., Magara, S., & Cancedda, L. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00054 · Cited by 141
“The recently developed technique for reprogramming somatic cells has opened the possibility of studying patient-derived neurons as a valuable tool for modeling neurological diseases (Takahashi et al., 2007; Park et al., 2008).”
MethodVenables, J. P., Lapasset, L., Gadéa, G., Fort, P., Klinck, R., Irimia, M., Vignal, E., Thibault, P., Prinos, P., Chabot, B., et al. (2013) · Nature Communications · doi:10.1038/ncomms3480 · Cited by 153
Gai, H., Leung, E., Costantino, P. D., Aguila, J. R., Nguyen, D. M., Fink, L., Ward, D., & Ma, Y.-P. (2009) · Cell Biology International · doi:10.1016/j.cellbi.2009.08.008 · Cited by 138
“…of iPS cells, which can be derived from fibroblast cell cultures by viral transduction of as few as 2e4 transcription factors (Huangfu et al., 2008; Park et al., 2008; Takahashi et al., 2007). iPS cells are indistinguishable from ES cells, have the ability to form teratomas, and contribute to the…”
BackgroundSmith, A. S. T., Macadangdang, J. R., Leung, W. W., Laflamme, M. A., & Kim, D. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.12.002 · Cited by 153
“…platforms with which to study inheritable diseases such as long QT syndrome, amyotrophic lateral sclerosis, Down's syndrome, spinal muscular atrophy, Duchenne and Becker muscular dystrophies, and Huntington's disease (Dimos et al., 2008; Ebert et al., 2009; Itzhaki et al., 2011; Park et al., 2008).”
Reprogrammed Cells for Disease Modeling and Regenerative Medicine
Cherry, A. B. C., & Daley, G. Q. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-163324 · Cited by 132
“Within 18 months of publication of the seminal paper describing mouse reprogramming, three independent laboratories reported successful derivation of human iPS cells (9–11), and shortly thereafter two groups produced iPS cells from patients with a multitude of diseases (12, 13).”
Self-citationInduced pluripotent stem cells: developmental biology to regenerative medicine
Nelson, T. J., Martinez‐Fernandez, A., & Terzic, A. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.159 · Cited by 128
“molecular profiling for diagnostic studies (5), or applied to preclinical models to quantify the regenerative potential of”
BackgroundModeling Dravet syndrome using induced pluripotent stem cells (iPSCs) and directly converted neurons
Jiao, J., Yang, Y., Shi, Y., Chen, J., Gao, R., Fan, Y., Yao, H., Liao, W., Sun, X., & Gao, S. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt275 · Cited by 141
Burrows, C. K., Banovich, N. E., Pavlovic, B. J., Patterson, K. M., Romero, I. G., Pritchard, J. K., & Gilad, Y. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1005793 · Cited by 136
Differentiation of induced pluripotent stem cells into functional oligodendrocytes
Czepiel, M., Balasubramaniyan, V., Schaafsma, W., Stančić, M., Mikkers, H., Huisman, C., Boddeke, E., & Copray, S. (2011) · Glia · doi:10.1002/glia.21159 · Cited by 134
“The subsequent successful attempts to generate human iPS cells revealed their potential value for the clinic (Aasen et al., 2008; Park et al., 2008b; Takahashi et al., 2007; Yu et al., 2007).”
BackgroundSustained synchronized neuronal network activity in a human astrocyte co-culture system
Kuijlaars, J., Oyelami, T., Diels, A., Rohrbacher, J., Versweyveld, S., Meneghello, G., Tuefferd, M., Verstraelen, P., Detrez, J. R., Verschuuren, M., et al. (2016) · Scientific Reports · doi:10.1038/srep36529 · Cited by 153
Denton, K. R., Lei, L., Grenier, J. M., Rodionov, V., Blackstone, C. D., & Li, X.-J. (2013) · Stem Cells · doi:10.1002/stem.1569 · Cited by 150
Sánchez‐Danés, A., Consiglio, A., Richaud, Y., Rodríguez-Pizà, I., Dehay, B., Edel, M. J., Bové, J., Memo, M., Vila, M., Raya, Á., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.054 · Cited by 128
“…enabled the deri-vation of patient-specific pluripotent cells, providing valuable experimental platforms to model human disease (Dimos et al. , 2008; Park et al. , 2008a; Ebert et al. , 2009; Soldner et al. , 2009; Agarwal et al. , 2010) and opening the possibility of implementing patient-matched…”
Viđarsson, H., Hyllner, J., & Sartipy, P. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9113-x · Cited by 118
“In addition, iPS cells derived from patients suffering from various cardiac diseases or disorders, such as channelopathies or congenital heart disease, are expected to become important tools for investigations of new treatment opportunities, as have been suggested in other disease areas [79, 80].”
Background3D Printed Neural Regeneration Devices
Joung, D., Lavoie, N., Guo, S., Park, S. H., Parr, A. M., & McAlpine, M. C. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201906237 · Cited by 144
TGF-β Family Signaling in Embryonic and Somatic Stem-Cell Renewal and DifferentiationPreprint
Mullen, A. C., & Wrana, J. L. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022186 · Cited by 149
Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease
Panicker, L. M., Miller, D., Park, T. S., Patel, B., Azevedo, J. L., Awad, O., Masood, M. A., Veenstra, T. D., Goldin, E., Stubblefield, B. K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207889109 · Cited by 129
“The assay for GC enzymatic activity in cells was carried out as described (8).”
BackgroundMethodWada, N., Wang, B., Lin, N.-H., Laslett, A., Gronthos, S., & Bartold, P. (2011) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2011.01358.x · Cited by 129
Kim, J., & Orkin, S. H. (2011) · Genome Medicine · doi:10.1186/gm291 · Cited by 127
Fong, H., Wang, C., Knoferle, J., Walker, D., Balestra, M. E., Tong, L. M., Leung, L., Ring, K. L., Seeley, W. W., Karydas, A., et al. (2013) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.08.001 · Cited by 122
Human iPS Cell-Based Therapy: Considerations Before Clinical Applications
Sun, N., Longaker, M., & Wu, J. C. (2010) · Cell Cycle · doi:10.4161/cc.9.5.10827 · Cited by 127
In Vitro Microfluidic Models for Neurodegenerative Disorders
Osaki, T., Shin, Y., Sivathanu, V., Campisi, M., & Kamm, R. D. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700489 · Cited by 155
Targeting innate immunity for neurodegenerative disorders of the central nervous system
Andreasson, K. I., Bachstetter, A. D., Colonna, M., Ginhoux, F., Holmes, C., Lamb, B., Landreth, G., Lee, D. C., Low, D., Lynch, M. A., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13667 · Cited by 126
“© 2016 International Society for Neurochemistry, J. Neurochem. (2016) 138, 653--693 653 JOURNAL OF NEUROCHEMISTRY | 2016 | 138 | 653–693 doi: 10.”
Kobari, L., Yates, F., Oudrhiri, N., Francina, A., Kiger, L., Mazurier, C., Rouzbeh, S., Nemer, W. E., Hebert, N., Giarratana, M., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.055566 · Cited by 126
“This technology provides a powerful new tool to investigate tissue differentiation(3-8) and to model genetic diseases in order to explore their physiopathology, providing new concepts of treatment.(9,10) It also opens the way to the production of patient-specific cells for cell therapy.”
MethodEngineering of Human Pluripotent Stem Cells by AAV-mediated Gene Targeting
Khan, I., Hirata, R. K., Wang, P.-R., Li, Y., Kho, J., Nelson, A., Huo, Y., Zavaljevski, M., Ware, C. B., & Russell, D. W. (2010) · Molecular Therapy · doi:10.1038/mt.2010.55 · Cited by 114
Pluripotency: Toward a gold standard for human ES and iPS cells
Smith, K. P., Luong, M. X., & Stein, G. S. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21681 · Cited by 123
“IPS technology holds enormous promise as it raises the prospect of derivation of disease-specific (Dimos et al., 2008; Park et al., 2008) and, potentially, patient-specific pluripotent cells (Yamanaka, 2007).”
BackgroundMesenchymal stromal cells from human perinatal tissues: From biology to cell therapy
Sancricca, C. (2010) · World Journal of Stem Cells · doi:10.4252/wjsc.v2.i4.81 · Cited by 136
Moretti, A., Bellin, M., Jung, C. B., Thies, T., Takashima, Y., Bernshausen, A., Schiemann, M., Fischer, S., Moosmang, S., Smith, A. G., et al. (2009) · The FASEB Journal · doi:10.1096/fj.09-139477 · Cited by 113
Sabapathy, V., & Kumar, S. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12839 · Cited by 129
Pasquale, E. D., Lodola, F., Miragoli, M., Denegri, M., Avelino-Cruz, J. E., Buonocore, M., Nakahama, H., Portararo, P., Bloise, R., Napolitano, C., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.369 · Cited by 133
Hematopoietic Development from Human Induced Pluripotent Stem Cells
Lengerke, C., Grauer, M., Niebuhr, N., Riedt, T., Kanz, L., Park, I.-H., & Daley, G. Q. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04606.x · Cited by 121
Self-citationIn vivo modeling of human neuron dynamics and Down syndrome
Real, R., Peter, M., Trabalza, A., Khan, S., Smith, M. A., Dopp, J., Barnes, S. J., Momoh, A., Strano, A., Volpi, E., et al. (2018) · Science · doi:10.1126/science.aau1810 · Cited by 120
“2, non-demented control) (53) and trisomic human iPSCs (Ts21-1) (54) (Fig.”
Kawasaki, Y., Oda, H., Ito, J., Niwa, A., Tanaka, T., Hijikata, A., Seki, R., Nagahashi, A., Osawa, M., Asaka, I., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39960 · Cited by 138
“Due to their pluripotency, patient-derived iPSCs can be differentiated into affected cell types and recapitulate the in vitro cellular phenotype of the disease (20), which has created a new field of disease modeling.”
BackgroundFarra, N., Zhang, W.-B., Pasceri, P., Eubanks, J. H., Salter, M. W., & Ellis, J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.180 · Cited by 121
Hosoyama, T., McGivern, J. V., Dyke, J. M. V., Ebert, A. D., & Suzuki, M. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2013-0143 · Cited by 132
Barzilay, R., Melamed, E., & Offen, D. (2009) · Stem Cells · doi:10.1002/stem.172 · Cited by 117
From Genomics to Gene Therapy: Induced Pluripotent Stem Cells Meet Genome Editing
Hotta, A., & Yamanaka, S. (2015) · Annual Review of Genetics · doi:10.1146/annurev-genet-112414-054926 · Cited by 124
Induced Pluripotent Stem Cells in Cardiovascular Drug Discovery
Mercola, M. A., Colas, A. R., & Willems, E. (2013) · Circulation Research · doi:10.1161/circresaha.111.250266 · Cited by 127
Caine, S., Heraud, P., Tobin, M. J., McNaughton, D., & Bernard, C. C. A. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.033 · Cited by 115
“Furthermore, apart from the ability to study diseased tissue in animal models, the recent discovery of induced pluripotent stem cells (iPS) from which disease specific cell lines can be developed, provides an opportunity to recapitulate the formation of pathological tissue in vitro (Park et al., 2008).”
BackgroundDeriving Excitatory Neurons of the Neocortex from Pluripotent Stem Cells
Hansen, D. V., Rubenstein, J. L. R., & Kriegstein, A. R. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.006 · Cited by 127
“…disease, Huntington's disease, Down's syndrome, familial dysautonomia, Rett syndrome, and schizophrenia (Brennand et al., 2011; Dimos et al., 2008; Ebert et al., 2009; Hotta et al., 2009; Lee et al., 2009; Marchetto et al., 2010; Nguyen et al., 2011; Park et al., 2008a; Soldner et al., 2009).”
Towards stem cell replacement therapies for Parkinson’s disease
Arenas, E. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.037 · Cited by 100
Neuroinflammatory paradigms in lysosomal storage diseases
Bosch, M. E., & Kielian, T. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00417 · Cited by 126
“…have provided valuable information concerning the downstream sequelae of LSDs where the putative function of mutated molecules remains to be identified (Pearce et al., 1999; PersaudSawin et al., 2002; Huang et al., 2005; Park et al., 2008; Tuxworth et al., 2011; Cotman and Staropoli, 2012).”
BackgroundGeneration of Induced Pluripotent Stem Cell Lines from Friedreich Ataxia Patients
Liu, J., Verma, P., Evans-Galea, M. V., Delatycki, M., Michalska, A., Leung, J., Crombie, D. E., Sarsero, J., Williamson, R., Dottori, M., et al. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9210-x · Cited by 115
“However, there was variable but persistent expression of the retroviral c-MYC and KLF4 transgenes in the iPS cell lines, a trend previously reported for other human iPS cells [7, 10, 28–31] and pig iPS cells Fig.”
Emerging trends in organ-on-a-chip systems for drug screening
Wang, Y., Gao, Y., Pan, Y., Zhou, D., Liu, Y., Yin, Y. B., Yang, J., Wang, Y., & Song, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.006 · Cited by 132
Human-induced pluripotent stem cells: potential for neurodegenerative diseases
Ross, C. A., & Akimov, S. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu204 · Cited by 111
“1) has opened the era of studying cellular disease phenotypes in patient-derived cell models (10,18).”
BackgroundFernández-Checa, J. C., Bagnaninchi, P., Ye, H., Sancho‐Bru, P., Falcón‐Pérez, J. M., Royo, F., García‐Ruiz, C., Konu, Ö., Miranda, J. P., Lunov, O., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.021 · Cited by 131
Stem cells for skeletal muscle repair
Shadrach, J., & Wagers, A. (2011) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0027 · Cited by 113
Molecular basis of pharmacotherapies for cognition in Down syndrome
Gardiner, K. (2009) · TIPS - Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.10.010 · Cited by 113
“An alternative cell culture system might come from recent advances in developing stem cell (iPS) lines from human fibroblasts followed by their differentiation to neural cell types [66].”
BackgroundModeling Alzheimer's disease with human induced pluripotent stem (iPS) cells
Mungenast, A. E., Siegert, S., & Tsai, L. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.11.010 · Cited by 136
“…Juvenile diabetes mellitus, Huntington disease (Consortium, 2012; N. Zhang, 2010; Q. Zhang, 2010), and Lesch–Nyhan syndrome (Mattis et al., 2015; Park et al., 2008) and AD (Choi et al., 2014; Hossini et al., 2015; Iovino Please cite this article as: Mungenast, A.E., et al., Modeling…”
BackgroundInvestigating monogenic and complex diseases with pluripotent stem cells
Zhu, H., Lensch, M. W., Cahan, P., & Daley, G. Q. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2951 · Cited by 104
Self-citationNicolas, C. T., Hickey, R., Chen, H. S., Mao, S. A., Higuita, M. L., Wang, Y., & Nyberg, S. L. (2016) · Stem Cells · doi:10.1002/stem.2500 · Cited by 129
Neural Stem Cell Biology in Vertebrates and Invertebrates: More Alike than Different?
Brand, A. H., & Livesey, F. J. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.016 · Cited by 112
Telugu, B., Ezashi, T., & Roberts, R. (2010) · International Journal of Developmental Biology · doi:10.1387/ijdb.103200bt · Cited by 111
“Therefore, the reports that mouse fibroblasts (Takahashi and Yamanaka, 2006) and human somatic cells (Lowry et al., 2008; Park et al., 2008a; Park et al., 2008b; Takahashi et al., 2007; Yu et al., 2007) could be re-programmed empirically to a pluripotent state to create induced pluripotent stem cells (iPSC), with prop…”
BackgroundLiras, A. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-131 · Cited by 112
“... with iPSCs from skin fibroblasts, differentiated to insulinsecreting pancreatic islets [54]; in lateral amyotrophic sclerosis (Lou Gehrig disease) [55]; and in many other conditions such as adenosine deaminase deficiency combined with severe immunodeficiency, Shwachman-Bodian-Diamond syndrome, type III Gaucher dis…”
BackgroundPulp-dentin regeneration: current approaches and challenges
Jung, C., Kim, S., Sun, T., Cho, Y., & Song, M. (2019) · Journal of Tissue Engineering · doi:10.1177/2041731418819263 · Cited by 139
Dental Stem Cells and Their Sources
Sedgley, C., & Botero, T. M. (2012) · Dental Clinics of North America · doi:10.1016/j.cden.2012.05.004 · Cited by 142
Gandre-Babbe, S., Paluru, P. C., Aribeana, C. N., Chou, S. T., Bresolin, S., Lu, L., Sullivan, S., Tasian, S., Weng, J. M., Favre, H., et al. (2011) · Blood · doi:10.1182/blood-2013-01-478412 · Cited by 109
Pluripotent Stem Cells and Disease Modeling
Colman, A., & Dreesen, O. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.08.010 · Cited by 109
“The advent of induced pluripotent stem cells (iPSCs) has transformed the prospects for disease modeling (Takahashi and Yamanaka, 2006; Park et al., 2008; Rubin, 2008): iPSCs can be made with cells taken from babies or adults of all ages with full medical records and suffering from virtually any…”
BackgroundInduced pluripotent stem cell models from X-linked adrenoleukodystrophy patients
Jang, J., Kang, H., Kim, H., Kim, J. Y., Huh, Y. J., Kim, D., Yoo, J., Lee, J., Lim, B., Lee, J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22486 · Cited by 109
“A recent introduction to iPSC technology opened a new avenue not only for cell replacement therapy,(29) but also for disease modeling.(30) In this study, we successfully generated iPSC lines from fibroblasts of patients with 2 major subtypes of X-ALD, the most severe, CCALD, and late onset AMN, and differentiated them…”
BackgroundSelf-citationJang, J., Yoo, J.-E., Lee, J., Lee, D. R., Kim, J. Y., Huh, Y. J., Kim, D., Park, C., Hwang, D., Kim, H.-S., et al. (2012) · Experimental & Molecular Medicine · doi:10.3858/emm.2012.44.3.015 · Cited by 111
“) and quantitative RT-PCR was carried out using specific primers (Park et al., 2008).”
BackgroundMethodInfluentialEmerging concepts in neural stem cell research: autologous repair and cell-based disease modelling
Koch, P., Kokaia, Z., Lindvall, O., & Brüstle, O. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70202-9 · Cited by 100
iPS Programmed Without c-MYC Yield Proficient Cardiogenesis for Functional Heart Chimerism
Martinez‐Fernandez, A., Nelson, T. J., Yamada, S., Reyes, S., Alekseev, A. E., Pérez-Terzic, C. M., Ikeda, Y., & Terzic, A. (2009) · Circulation Research · doi:10.1161/circresaha.109.203109 · Cited by 98
Stem Cells to Pancreatic β-Cells: New Sources for Diabetes Cell Therapy
Guo, T., & Hebrok, M. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0004 · Cited by 106
Stem cell sources for tooth regeneration: current status and future prospects
Otsu, K., Kumakami‐Sakano, M., Fujiwara, N., Kikuchi, K., Keller, L., Lesot, H., & Harada, H. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00036 · Cited by 109
“…of iPS cells specific for various diseases, including Parkinson’s disease, amyotrophic lateral sclerosis, and familial dysautonomia, in studies to elucidate the mechanism of their development and progression and to search for suitable drugs (Dimos et al., 2008; Park et al., 2008; Lee et al., 2009).”
BackgroundChun, Y. S., Chaudhari, P., & Jang, Y.-Y. (2010) · International Journal of Biological Sciences · doi:10.7150/ijbs.6.796 · Cited by 113
“In addition, derivation of patient-specific iPSCs for various diseases/disorders has also been reported (5-9).”
BackgroundMatsa, E., Ahrens, J. H., & Wu, J. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00036.2015 · Cited by 105
Cheng, P.-H., Li, C.-L., Chang, Y.-F., Tsai, S.-J., Lai, Y.-Y., Chan, A. W. S., Chen, C.-M., & Yang, S.-H. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.05.025 · Cited by 98
“The model of HD individual-derived induced pluripotent stem cells (HD-iPSCs) is a unique platform to study endogenous HTT in HD research.(9,10) Therefore, we used HD-iPSCs (GM23225) purchased and permitted from the Coriell Institute in this study and differentiated these cells into neuronal cells.”
MethodMicroRNA Profiling Reveals Two Distinct p53-Related Human Pluripotent Stem Cell States
Neveu, P. A., Kye, M. J., Qi, S., Buchholz, D. E., Clegg, D., Şahin, M., Park, I., Kim, K., Daley, G. Q., Kornblum, H. I., et al. (2010) · Cell stem cell · doi:10.1016/j.stem.2010.11.012 · Cited by 99
“The iPSCs were generated by different sets of reprogramming factors and different delivery methods (virus [Yu et al., 2007; Park et al., 2008b, 2008a; Chan et al., 2009], episome [Yu et al., 2009], or proteins [Kim et al., 2009]; Table S1) in ten reprogramming experiments from different groups with…”
MethodSelf-citationFeeder- and serum-free establishment and expansion of human induced pluripotent stem cells
Totonchi, M., Taei, A., Seifinejad, A., Tabebordbar, M., Rassouli, H., Farrokhi, A., Gourabi, H., Aghdami, N., Salekdeh, G. H., & Baharvand, H. (2009) · The International Journal of Developmental Biology · doi:10.1387/ijdb.092903mt · Cited by 103
“In hiPSCs, retroviral expression of human Oct4, Sox2, c-Myc, and Klf4 is silenced during hiPSC generation and complemented by reactivation of expression from the endogenous gene loci (Hotta and Ellis, 2008; Park et al., 2008b; Takahashi et al., 2007).”
BackgroundInfluentialLin, B., Li, Y., Han, L., Kaplan, A. D., Ao, Y., Kalra, S., Bett, G. C. L., Rasmusson, R. L., Denning, C. N., & Yang, L. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.019505 · Cited by 122
“RESULTS Characterizations of DMD patient-specific iPSCs In this study, we obtained two previously established DMD iPSC lines, DMD-iPS1 (Park et al., 2008) and DMD15 (Dick et al.”
BackgroundMethodResultInfluentialBan, K., Park, H., Kim, S., Andukuri, A., Cho, K.-W., Hwang, J., Cha, H.-J., Kim, S. Y., Kim, W., Jun, H.-W., et al. (2014) · ACS Nano · doi:10.1021/nn504617g · Cited by 103
Kane, N. M., Xiao, Q., Baker, A. H., Luo, Z., Xu, Q., & Emanueli, C. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.10.004 · Cited by 89
Modeling human neurological disorders with induced pluripotent stem cells
Imaizumi, Y., & Okano, H. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12625 · Cited by 111
Thatava, T., Kudva, Y. C., Edukulla, R., Squillace, K. A., Lamo, J. G. D., Khan, Y. K., Sakuma, T., Ohmine, S., Terzic, A., & Ikeda, Y. (2012) · Molecular Therapy · doi:10.1038/mt.2012.245 · Cited by 98
Steward, M., Sridhar, A., & Meyer, J. S. (2012) · Current topics in microbiology and immunology · doi:10.1007/82_2012_302 · Cited by 53
“…important in diseases such as ALS which possess a complex phenotype and no effective treatment exists to date. hiPSCs have been derived from ALS patients that mirror the disease phenotype and efforts are being undertaken to understand the disease pathology (Dimos et al. 2008; Park et al. 2008).”
BackgroundYang, P., Wang, Y.-X., Chen, J.-Y., Li, H., Kang, L., Zhang, Y., Chen, S., Zhu, B., & Gao, S.-R. (2011) · Stem Cells · doi:10.1002/stem.634 · Cited by 101
Schnerch, A., Cerdan, C., & Bhatia, M. (2010) · Stem Cells · doi:10.1002/stem.298 · Cited by 101
Reprogramming of Human Fibroblasts to Induced Pluripotent Stem Cells under Xeno-free Conditions
Rodríguez-Pizà, I., Richaud‐Patín, Y., Vassena, R., Gonzãlez, F., Barrero, M. J., Veiga, A., Raya, Á., & Belmonte, J. C. I. (2009) · Stem Cells · doi:10.1002/stem.248 · Cited by 101
Primary cells and stem cells in drug discovery: emerging tools for high-throughput screening
Eglen, R., & Reisine, T. (2011) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2010.0305 · Cited by 100
Induced pluripotent stem cells and reprogramming: seeing the science through the hype
Belmonte, J. C. I., Ellis, J., Hochedlinger, K., & Yamanaka, S. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2700 · Cited by 98
“The first advance has been the proof-of-principle demonstration that iPS cells can be derived from skin cells from patients with a variety of disease”
BackgroundSelf-citationChae, J., Kim, D., Lee, N., Jeon, Y.-J., Jeon, I., Kwon, J., Kim, J., Soh, Y., Lee, D., Seo, K.-S., et al. (2012) · Biochemical Journal · doi:10.1042/bj20111495 · Cited by 106
Self-citationHo, J. C.-Y., Zhou, T., Lai, W., Huang, Y., Chan, Y.-C., Li, X., Wong, N. L.-Y., Li, Y., Au, K., Guo, D., et al. (2011) · Aging · doi:10.18632/aging.100277 · Cited by 100
“iPSC cell lines retain the ability to differentiate into specific lineages, enabling the study of a given disease in a patient-specific and cell-specific context [13].”
BackgroundiPS cell technology in regenerative medicine
Lengner, C. J. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05213.x · Cited by 95
Diversity among POU transcription factors in chromatin recognition and cell fate reprogramming
Malik, V., Zimmer, D., & Jauch, R. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2748-5 · Cited by 98
The tumourigenicity of iPS cells and their differentiated derivates
Liu, Z.-Q., Tang, Y., Lu, S.-H., Zhou, J., Du, Z., Duan, C., Li, Z., & Wang, C.-Y. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12062 · Cited by 98
Current status of drug screening and disease modelling in human pluripotent stem cells
Rajamohan, D., Matsa, E., Kalra, S., Crutchley, J., Patel, A. K., George, V. T., & Denning, C. N. (2012) · BioEssays · doi:10.1002/bies.201200053 · Cited by 104
An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity
Cisbani, G., & Cicchetti, F. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.121 · Cited by 107
“Notably, primary fibroblasts can be easily collected from patients and differentiated into neuronal cells.(127,130) Importantly, mHtt does not impair the process of converting the cells into neuronal progenitors or mature neurons.”
BackgroundGunaseeli, I., Doss, M., Antzelevitch, C., Hescheler, J., & Sachinidis, A. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790514480 · Cited by 98
“Such disease-specific stem cells offer an unprecedented opportunity to recapitulate both normal and pathologic human tissue formation in vitro, thereby enabling disease investigation and drug development [28].”
BackgroundMollamohammadi, S., Taei, A., Pakzad, M., Totonchi, M., Seifinejad, A., Masoudi, N., & Baharvand, H. (2009) · Human Reproduction · doi:10.1093/humrep/dep244 · Cited by 102
“…et al., 2007; Yu et al., 2007; Aasen et al., 2008; Dimos et al., 2008; Huangfu et al., 2008; Lowry et al., 2008; Maherali et al., 2008; Nakagawa et al., 2008; Park et al., 2008a, b; Ebert et al., 2009; Li et al., 2009), providing an invaluable contribution to the field of regenerative medicine.”
BackgroundNandan, M., & Yang, V. W. (2009) · Histology and Histopathology · doi:10.14670/hh-24.1343 · Cited by 98
Koyuncu, S., Sáez, I., Lee, H. J., Gutiérrez-García, R., Pokrzywa, W., Fatima, A., Hoppe, T., & Vı́lchez, D. (2018) · Nature Communications · doi:10.1038/s41467-018-05320-3 · Cited by 105
Application of biomaterials to advance induced pluripotent stem cell research and therapy
Tong, Z., Solanki, A., Hamilos, A. E., Levy, O., Wen, K., Yin, X., & Karp, J. M. (2015) · The EMBO Journal · doi:10.15252/embj.201490756 · Cited by 90
“Nat Biotechnol 28:”
BackgroundThe potential of induced pluripotent stem cell derived hepatocytes
Hannoun, Z., Steichen, C., Dianat, N., Weber, A., & Dubart‐Kupperschmitt, A. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.025 · Cited by 107
“source including patients with a wide range of disease backgrounds [73].”
BackgroundFreund, C. M. A. H., & Mummery, C. L. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22164 · Cited by 91
“…only at low efficiency ( 0.01%), iPS cells have now been generated from a range of different somatic cells, including mouse liver and pancreatic cells [Aoi et al., 2008; Stadtfeld et al., 2008a] and human keratinocytes from hair and cells from bone marrow [Aasen et al., 2008; Park et al., 2008].”
BackgroundInfluential
Metadata
- Authors
- Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- University of Washington (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Daley, George Q.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 134
- Issue
- 5
- Pages
- 877-886
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC2633781
- OpenAlex
- W2157645703
- Cited by
- 2,196
- References
- 34
- Citations by year
- 2026: 20 · 2025: 32 · 2024: 38 · 2023: 51 · 2022: 62 · 2021: 75 · 2020: 89 · 2019: 73 · 2018: 71 · 2017: 108 · 2016: 125 · 2015: 144 · 2014: 139 · 2013: 204 · 2012: 272
- FWCI
- 95.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (DP1OD000256)
- National Heart, Lung, and Blood Institute (R01HL079582)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK059279)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- induced pluripotent stem cells, genetic disorders, Mendelian inheritance, multifactorial inheritance, ADA-SCID, Duchenne muscular dystrophy, Becker muscular dystrophy, Parkinson's disease, Huntington's disease, Down syndrome, Lesch-Nyhan syndrome, in vitro disease model, drug development
- MeSH terms
- Bone Marrow Cells, Cell Line, Fibroblasts, Humans, Karyotyping, Mutation, Genetic Diseases, Inborn, Pluripotent Stem Cells, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
